Evaluation of Ketamine's Antidepressant Effects in Patients with Major Depressive Disorder

The primary objective of the study is to monitor the **antidepressant** effects of **ketamine** in patients diagnosed with **major depressive disorder** (MDD). This is clinically relevant as MDD is a prevalent and debilitating mental health condition, and ketamine has shown potential as a rapid-acting antidepressant, offering a novel therapeutic option for patients who may not respond to traditional treatments.

The clinical trial focuses on individuals diagnosed with **major depressive disorder**. The study population includes both male and female participants, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the effects of ketamine in patients diagnosed with **major depressive disorder**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is June 1, 2024, with an anticipated end date of May 31, 2025. The trial will involve multiple study visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will be randomly assigned to receive either the investigational product or a control, with neither the participants nor the investigators aware of the group assignments to maintain blinding.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their response to the treatment and assess any adverse effects. These visits are crucial for collecting data on the primary and secondary endpoints, which, although not specified, typically include measures of efficacy and safety. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected duration of participant involvement will align with the overall trial timeline, spanning approximately one year. However, participants may be subject to early termination from the study if they experience significant adverse effects, fail to adhere to the study protocol, or withdraw consent. The trial's methodology and design ensure rigorous evaluation of the investigational product's effects, contributing valuable insights into its potential therapeutic benefits for individuals with major depressive disorder.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on June 1, 2024, with an estimated completion date of May 31, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for assessment, are not specified in the available information. The trial's focus is on obtaining robust efficacy data to support the therapeutic claims of the investigational product.